{"id":"prevenar-13-pneumovax-23","safety":{"commonSideEffects":[{"rate":"30–50","effect":"Injection site pain, erythema, or swelling"},{"rate":"20–40","effect":"Myalgia"},{"rate":"15–30","effect":"Fatigue"},{"rate":"15–25","effect":"Headache"},{"rate":"5–15","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prevenar 13 is a conjugate vaccine that elicits T-cell dependent immunity against 13 pneumococcal serotypes by linking polysaccharide antigens to a protein carrier. Pneumovax 23 is a polysaccharide vaccine covering 23 serotypes that provides additional coverage. The sequential administration leverages the immunological priming from Prevenar 13 to enhance the response to Pneumovax 23, resulting in superior and more durable protection against invasive pneumococcal disease.","oneSentence":"This sequential pneumococcal vaccination regimen primes and boosts the immune system against 13 common pneumococcal serotypes (Prevenar 13) followed by 23 serotypes (Pneumovax 23) to provide broad protection against pneumococcal disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:35.853Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in adults"},{"name":"Prevention of pneumococcal pneumonia and related infections in high-risk populations"}]},"trialDetails":[{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT07333352","phase":"PHASE2","title":"PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months","status":"RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2025-09-11","conditions":"Pneumococcal Infectious Disease","enrollment":480},{"nctId":"NCT06675032","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-27","conditions":"Pneumococcal Infectious Disease","enrollment":230},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT04583618","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-10-08","conditions":"Pneumococcal Immunization","enrollment":750},{"nctId":"NCT03104075","phase":"PHASE4","title":"Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines","status":"COMPLETED","sponsor":"The Jackson Laboratory","startDate":"2017-04-17","conditions":"Pneumonia, Aging","enrollment":40},{"nctId":"NCT04460235","phase":"PHASE4","title":"Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2021-09-07","conditions":"Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin","enrollment":160},{"nctId":"NCT06703203","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2024-08-27","conditions":"Pneumococcal Vaccines","enrollment":450},{"nctId":"NCT05982314","phase":"PHASE1, PHASE2","title":"Extension Safety and Immunogenicity Study of GPNV-001","status":"COMPLETED","sponsor":"GPN Vaccines","startDate":"2023-07-17","conditions":"Pneumococcal Infections","enrollment":60},{"nctId":"NCT05408429","phase":"PHASE3","title":"Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-06-24","conditions":"Pneumococcal Disease","enrollment":356},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT04841369","phase":"PHASE3","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2021-04-13","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":3420},{"nctId":"NCT03803202","phase":"PHASE1, PHASE2","title":"A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-01-24","conditions":"Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease","enrollment":630},{"nctId":"NCT02637583","phase":"PHASE4","title":"Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels","status":"COMPLETED","sponsor":"Jena University Hospital","startDate":"2017-10-18","conditions":"Pneumococcal Infections","enrollment":123},{"nctId":"NCT03565900","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-12","conditions":"Pneumococcal Infections","enrollment":277},{"nctId":"NCT05939219","phase":"NA","title":"Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-07-01","conditions":"Healthy Volunteers","enrollment":2346},{"nctId":"NCT02255227","phase":"PHASE2","title":"Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-04-13","conditions":"Infections, Pneumococcal, Bowel Diseases, Inflammatory","enrollment":104},{"nctId":"NCT03921424","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-11-05","conditions":"Pneumococcal Infections","enrollment":407},{"nctId":"NCT05316831","phase":"PHASE4","title":"Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Region Örebro County","startDate":"2019-01-01","conditions":"CLL, Vaccine Response","enrollment":77},{"nctId":"NCT03762824","phase":"PHASE4","title":"Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease","status":"COMPLETED","sponsor":"Region Skane","startDate":"2016-06-14","conditions":"Rheumatoid Arthritis, Systemic Lupus, Sjögren Syndrome","enrollment":300},{"nctId":"NCT05481801","phase":"","title":"Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-2)","status":"COMPLETED","sponsor":"Castilla-La Mancha Health Service","startDate":"2022-09-01","conditions":"Type 1 Diabetes","enrollment":300},{"nctId":"NCT03885934","phase":"PHASE3","title":"Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-25","conditions":"Pneumococcal Infections","enrollment":606},{"nctId":"NCT05602480","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate PCV13 in Healthy People","status":"UNKNOWN","sponsor":"Wuhan BravoVax Co., Ltd.","startDate":"2022-11-01","conditions":"Pneumococcal Infections","enrollment":264},{"nctId":"NCT03873727","phase":"PHASE2","title":"Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-08-27","conditions":"Splenectomised Patients","enrollment":39},{"nctId":"NCT02274415","phase":"PHASE2","title":"Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-09-16","conditions":"Invasive Pneumococcal Infections, Sickle Cells Disease","enrollment":116},{"nctId":"NCT02447718","phase":"PHASE4","title":"Vaccinating Children After Chemotherapy","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-11-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":156},{"nctId":"NCT03480802","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-06","conditions":"Pneumococcal Infections","enrollment":302},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT02547493","phase":"NA","title":"Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2016-03-03","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT00427895","phase":"PHASE3","title":"Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-02-27","conditions":"Pneumococcal Infections","enrollment":2141},{"nctId":"NCT02225587","phase":"PHASE3","title":"Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-28","conditions":"Pneumococcal Infections","enrollment":400},{"nctId":"NCT03480763","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-22","conditions":"Pneumococcal Infections","enrollment":652},{"nctId":"NCT02279589","phase":"PHASE2","title":"Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-12-04","conditions":"Pneumococcal Infection","enrollment":60},{"nctId":"NCT04875858","phase":"PHASE4","title":"Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2021-05-01","conditions":"Pneumococcal Infections","enrollment":254},{"nctId":"NCT04875819","phase":"PHASE4","title":"Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV","status":"RECRUITING","sponsor":"Thomas Benfield","startDate":"2021-04-28","conditions":"Hiv, Meningococcal Infections, Pneumococcal Infections","enrollment":55},{"nctId":"NCT03802994","phase":"EARLY_PHASE1","title":"Pneumococcal Conjugate Vaccine in Aging Renal Transplant","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-11-01","conditions":"Renal Transplantation, Aging","enrollment":57},{"nctId":"NCT03547167","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-16","conditions":"Pneumococcal Infections","enrollment":1515},{"nctId":"NCT03478254","phase":"","title":"Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).","status":"COMPLETED","sponsor":"Jesús Moreno Fernández","startDate":"2017-12-01","conditions":"Type 1 Diabetes Mellitus","enrollment":300},{"nctId":"NCT02012309","phase":"NA","title":"Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2014-08","conditions":"HIV, Pneumococcal Infections, Pneumococcal Vaccines","enrollment":60},{"nctId":"NCT04551248","phase":"","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2021-08-01","conditions":"Pneumococcal Vaccine Adverse Reaction","enrollment":1000000},{"nctId":"NCT01942174","phase":"PHASE3","title":"VACcination In Methotrexate Treated Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2013-09-27","conditions":"Rheumatoid Arthritis","enrollment":276},{"nctId":"NCT03039491","phase":"EARLY_PHASE1","title":"Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2015-09-01","conditions":"HIV Lipodystrophy, Aging","enrollment":160},{"nctId":"NCT02787863","phase":"PHASE4","title":"Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology","status":"COMPLETED","sponsor":"Mikhael Petrovich Kostinov","startDate":"2012-09-06","conditions":"Chronic Obstructive Pulmonary Disease, Asthma, Pneumococcal Infections","enrollment":219},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT03313037","phase":"PHASE2","title":"Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-10-10","conditions":"Pneumococcal Infections","enrollment":444},{"nctId":"NCT02573181","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-30","conditions":"Pneumococcal Infections","enrollment":253},{"nctId":"NCT02308540","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2015-01-12","conditions":"Pneumococcal Disease","enrollment":346},{"nctId":"NCT00980655","phase":"PHASE3","title":"Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01-18","conditions":"Vaccines, Pneumococcal Conjugate Vaccine","enrollment":251},{"nctId":"NCT01513551","phase":"PHASE2","title":"The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-03-13","conditions":"Pneumococcal Infections","enrollment":692},{"nctId":"NCT01307449","phase":"NA","title":"Systems Biology of PNEUMOVAX®23 and PREVNAR 13®","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-04","conditions":"Pneumococcal Infection","enrollment":88},{"nctId":"NCT03514979","phase":"PHASE2","title":"Acquired Immunodeficiency in ANCA Associated Vasculitis","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2018-06","conditions":"Systemic Vasculitis","enrollment":124},{"nctId":"NCT02072525","phase":"PHASE4","title":"A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-01","conditions":"Meningococcal","enrollment":359},{"nctId":"NCT01781871","phase":"PHASE4","title":"Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2013-01","conditions":"Kidney Transplantation, Liver Transplantation","enrollment":182},{"nctId":"NCT03095326","phase":"PHASE4","title":"Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2013-09-01","conditions":"Thalassemia, Pneumococcal Infection","enrollment":56},{"nctId":"NCT01654263","phase":"PHASE2","title":"A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-10-10","conditions":"Pneumococcal Infection","enrollment":884},{"nctId":"NCT02357823","phase":"","title":"Antibodies and Memory Cells Role After Different Pneumococcal Vaccines in HIV Adults","status":"WITHDRAWN","sponsor":"University of Siena","startDate":"2015-01","conditions":"HIV, Pneumococcal Infections","enrollment":""},{"nctId":"NCT02124161","phase":"PHASE4","title":"Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-09","conditions":"PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE","enrollment":882},{"nctId":"NCT02079207","phase":"PHASE3","title":"Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2013-12","conditions":"Pneumococcal Infections","enrollment":767},{"nctId":"NCT01892618","phase":"PHASE3","title":"Pneumococcal Vaccine in Untreated CLL Patients","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2013-08","conditions":"Chronic Lymphocytic Leukemia","enrollment":134},{"nctId":"NCT01432158","phase":"PHASE3","title":"Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-01","conditions":"Pneumococcal Disease","enrollment":4},{"nctId":"NCT02582047","phase":"PHASE4","title":"Influenza Vaccine and Pneumococcal Vaccine","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2012-10","conditions":"Influenza, Human, Pneumococcal Infections","enrollment":224},{"nctId":"NCT02558751","phase":"EARLY_PHASE1","title":"Pneumonia Vaccine in Aging HIV Positive Individuals","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2013-07","conditions":"Pneumococcal Infection","enrollment":51},{"nctId":"NCT02492438","phase":"PHASE4","title":"13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients","status":"COMPLETED","sponsor":"AZ Sint-Jan AV","startDate":"2013-02","conditions":"Chronic Kidney Failure","enrollment":154},{"nctId":"NCT00521586","phase":"PHASE3","title":"Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-09","conditions":"Influenza","enrollment":1116},{"nctId":"NCT01947010","phase":"PHASE4","title":"Pneumococcal Vaccination of Crohn Patients","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2013-07","conditions":"Crohns Disease","enrollment":151},{"nctId":"NCT00962780","phase":"PHASE3","title":"Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"HIV Infections, Pneumococcal Infections","enrollment":303},{"nctId":"NCT01619462","phase":"PHASE3","title":"Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children","status":"UNKNOWN","sponsor":"Papua New Guinea Institute of Medical Research","startDate":"2011-11","conditions":"Pneumonia, Meningitis, Bacteraemia","enrollment":200},{"nctId":"NCT01646398","phase":"PHASE3","title":"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine","enrollment":764},{"nctId":"NCT01432262","phase":"PHASE3","title":"13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-07","conditions":"Pneumococcal Infections","enrollment":324},{"nctId":"NCT01025336","phase":"PHASE3","title":"Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-12","conditions":"Healthy","enrollment":962},{"nctId":"NCT00492557","phase":"PHASE3","title":"Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-09","conditions":"Pneumococcal Infections","enrollment":1185},{"nctId":"NCT00562354","phase":"PHASE3","title":"Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-10","conditions":"Healthy","enrollment":271},{"nctId":"NCT00574548","phase":"PHASE3","title":"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-11","conditions":"Pneumococcal Vaccines","enrollment":720},{"nctId":"NCT00546572","phase":"PHASE3","title":"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-11","conditions":"Pneumococcal Infections","enrollment":938}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Prevenar 13 + Pneumovax 23","genericName":"Prevenar 13 + Pneumovax 23","companyName":"Poitiers University Hospital","companyId":"poitiers-university-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"This sequential pneumococcal vaccination regimen primes and boosts the immune system against 13 common pneumococcal serotypes (Prevenar 13) followed by 23 serotypes (Pneumovax 23) to provide broad protection against pneumococcal disease. Used for Prevention of invasive pneumococcal disease in adults, Prevention of pneumococcal pneumonia and related infections in high-risk populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}